Novo Nordisk Shares Drop Amid Profit Warnings and Growth Concerns
Originally Published 5 months ago — by Yahoo Finance
Novo Nordisk's stock declined for the third consecutive day following a downgrade by Bank of America and a cautious outlook for the year's sales growth, mainly due to weaker sales projections for key drugs Wegovy and Ozempic. The company also announced a new CEO to replace the ousted Lars Fruergaard Jørgensen.